Bosentan: A dual endothelin receptor antagonist

Expert Opinion on Investigational Drugs

Volumn 11, Issue 7, 2002, Pages 991-1002

  Rubin, Lewis J ^a   Roux, Sébastien ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bosentan; Endothelin; Endothelin receptor antagonism; Pulmonary arterial hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; BILE SALT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DILTIAZEM; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; HEPARIN; NIFEDIPINE; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; WARFARIN; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANADA; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; DISEASE COURSE; DOG; DRUG APPROVAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EUROPEAN UNION; EXERCISE; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HEART FAILURE; HEART FUNCTION; HUMAN; INHIBITION KINETICS; LUNG FUNCTION; NONHUMAN; PHYSICAL CAPACITY; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; SWITZERLAND; SYMPTOM; TERATOGENICITY; TESTIS DISEASE; THROMBOSIS; UNITED STATES; VASCULAR DISEASE; ANIMAL; BIOSYNTHESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; REVIEW;

ANIMAL; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMAN; HYPERTENSION, PULMONARY; MODELS, ANIMAL; RECEPTORS, ENDOTHELIN; SULFONAMIDES; ANIMALS; HUMANS;

EID: 0035986906     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.7.991     Document Type: Article

References (83)

1. The endothelin family of peptides: Local hormones with diverse roles in health and disease?
2. Endothelins
3. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells
4. Antiaggretory and hypotensive effects of endothelin-1 in beagle dogs: Role for prostacyclin
5. Enhanced coronary vasoconstriction to endothelin-B receptor activation in experimental congestive heart failure
6. Role of endothelin in the increased vascular tone of patients with essential hypertension
7. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease
8. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension
9. Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery
10. Altered endothelin receptor subtype expression in hepatic injury after ischemia/reperfusion
11. Clearance of circulating endothelin-1 by ETB receptors in rats
12. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes
13. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts
14. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C
15. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells
16. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis
17. B receptor subtypes
18. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins
19. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
20. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension
21. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension
22. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension
23. Endothelin-1 in the lungs of patients with pulmonary hypertension
24. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: Evidence for increased production of endothelin in pulmonary circulation
25. ACCP consensus statement: Primary pulmonary hypertension
26. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
27. Primary pulmonary hypertension
28. Primary pulmonary hypertension
29. Primary pulmonary hypertension: A national prospective study
30. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
31. Primary pulmonary hypertension: Case series from the United Kingdom
32. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients
33. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis
34. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
35. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension
36. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
37. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
38. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
39. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
40. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
41. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
42. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
43. Recognition and management of pulmonary hypertension
44. B-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats
45. B receptors
46. Endothelin receptors in cultured rat cardiac fibroblasts
47. B receptor-mediated contraction in human pulmonary resistance arteries
48. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
49. Endothelin antagonism with bosentan: A review of potential applications
50. B receptor antagonist, in the hind-limb vascular bed of the cat
51. Characterization of the pulmonary arterial response to endothelin-1 and bosentan in neonatal pigs
52. Differential effects of the mixed ET(A)/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release
53. Blockade of angiotensin II Type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms
54. Telemetry monitoring of pulmonary arterial pressure in freely moving rats
55. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
56. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats
57. The endothelin antagonist bosentan: Hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs
58. Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan
59. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension
60. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
61. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
62. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure
63. Effects of the endothelin receptor antagonist bosentan on ischaemia/reperfusion injury in rat skeletal muscle
64. B receptors
65. Mixed endothelin ET(A) and ET(B) antagonist bosentan inhibits oleic acid-induced lung plasma extravasation in mouse
66. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater
67. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
68. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
69. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects
70. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers
71. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
72. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin
73. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects
74. A drug interaction study between bosentan and ketoconazole and losartan
75. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
76. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
77. Bosentan therapy for pulmonary arterial hypertension
78. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial
79. Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure: Results of the ENABLE 1 and 2 trial program
80. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
81. Update of Reach-1 and Merit-hf clinical trials in heart failure
82. Raynaud's phenomenon
83. Epidemiological study of patients with systemic sclerosis in Tokyo